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ABSTRACT 
 
Background: 
 Acute pancreatitis is a common and a highly challenging clinical 
condition encountered in our day to day surgical practice. Severe pancreatitis 
being associated with high mortality, scoring systems has been devised to 
assess the severity. The Neutrophil-Lymphocyte Ratio (NLR) calculated 
from the WBC differential count provides a rapid indication of the extent of 
an inflammatory process. 
Aim of study: 
 To investigate if Neutrophil- Lmphocyte Ratio (NLR) can act as a 
single indicator in assessing the prognosis of acute pancreatitis. 
Materials & methods: 
 The NLR was calculated on 100 acute pancreatitis patients on day 0, 
day1 and day2 of admission. The NLR obtained was correlated with the 
severity of pancreatitis using Atlanta classification. 
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Results: 
 Of the 100 patients, 20 patients had severe acute pancreatitis. The 
NLR values calculated in severe acute pancreatitis was significantly higher 
than in mild acute pancreatitis on all 3 days (Day 0- 8.2 vs. 4.4; Day 1- 9.07 
vs. 5.08; Day 2- 10.89 vs. 4.52). 
Conclusion: 
 Elevation of Neutrophil Lymphocyte Ratio (NLR) during the first 
48hrs of admission is significantly associated with severe acute pancreatitis 
and can be used as a simple, single, cost-effective indicator in assessing 
severity of acute pancreatitis. 
Key words: Acute Pancreatitis, Neutrophil Lymphocyte Ratio (NLR), 
Severity 
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INTRODUCTION 
 
 
 
 Acute pancreatitis (AP) is an outcome of acute inflammation of 
pancreas with activation of the pancreatic enzymes. The Atlanta classifies 
acute pancreatitis into mild pancreatitis and severe pancreatitis. Though 
normally it is a self limiting process with 80 % having mild disease, 10% to 
20% of them have a rapidly progressive inflammatory response. Patients 
with mild pancreatitis have less than 1% mortality rate whereas even up to 
50% for those with severe pancreatitis.  
In Severe pancreatitis, adverse outcome is attributed to an 
uncontrolled systemic inflammatory response syndrome (SIRS), with 
progression to a multi-organ dysfunction syndrome (MODS). Hence to 
stratify the severity of the Acute Pancreatitis, Scoring Systems have been 
introduced which help in appropriate management and to improve the 
outcome.  
The scoring system currently regarded as the best for assessment of 
Acute Pancreatitis, namely the Acute Physiology and Chronic Health 
Evaluation (APACHE II), is labor intensive and is not being followed 
routinely for patients of pancreatitis treated outside Intensive Care Unit. 
Other scoring systems namely Ransons scoring system and Imrie scoring 
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system (Glascow scoring system) are also difficult to apply as there are 
many parameters.  
In India, pancreatitis seems to be more common among alcoholics. 
Being a developing nation, most of the affected families live in poverty. So, 
the hospital expenses in treatment of pancreatitis are a burden to them. Many 
investigations are required for calculating the above severity scoring systems 
which will increase the patient‟s cost. In order to predict the severity of the 
disease earlier, a simple scoring system is needed which will enable us to 
provide aggressive treatment for those progressing to severe pancreatitis and 
lower the morbidity and mortality. 
The white blood cell count is a routine serum hematological test that 
is already incorporated in many of the current Acute Pancreatitis scoring 
systems, and routinely performed on all surgical emergency admissions. 
Components of the total WBC count include neutrophils and lymphocytes, 
both of which can be used individually as markers of inflammation. 
 In Acute pancreatitis, Neutrophils are incorporated into the pancreas 
due to the action of inflammatory cytokines. These neutrophils propagate 
Systemic Inflammatory Response Syndrome (SIRS) and the inflammatory 
cascade in Acute Pancreatitis whereas lymphocyte depletion occurs in severe 
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sepsis, and is associated with a poor outcome. This lymphopenia has been 
previously associated with severe sepsis, bacteremia, and surgical stress.  
The Neutrophil-Lymphocyte ratio (NLR) is a measure of the 
divergence of these two WBC components, and may be more accurate than 
the total WBC or individual neutrophil and lymphocyte counts in predicting 
poor outcome. 
Thus the aim of my study is to check if NLR can be used as a single 
cost-effective tool to predict the severity of acute pancreatitis. 
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AIMS AND OBJECTIVES 
  
The aim of my study is to calculate the Neutrophilic Lymphocytic 
Ratio (NLR) among acute pancreatitis patients and to investigate if this ratio 
is helpful as a single predictor in assessing the prognosis of acute 
pancreatitis. 
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REVIEW OF LITERATURE 
 
HISTORICAL BACKGROUND: 
The pancreas is a hidden organ and was one of the last organs in the 
abdomen to be analyzed by anatomists, physiologists, physicians, and 
surgeons.1 Earliest reference dates back to the Babylonian Talmud which 
describes pancreas as the “finger of liver”. The word pancreas is derived 
from a Greek concept of pan kreas (meaning “all flesh”) based on the 
hypothesis by Hippocrates that all glandular structures were composed of 
flesh.2  
Vesalius was the first initiated the formal structural elucidation of 
pancreas. The formal structure of pancreas was first quoted by Vesalius. The 
physiologic function of pancreas was defined by R. de Graaf. The 
association of diabetes mellitus with pancreas was identified by O. 
Minkowski. With regard to the digestive property of pancreas, fat digestion 
was described by J. Purkinje and role of trypsin in proteolysis by W. 
Kuhne.2 
Nicholaes Tulp from Amsterdam was the first to describe acute 
pancreatitis in 1652. However, Guy Patin from Paris made a similar 
observation, but published a decade later.2 
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PANCREAS: 
The pancreas is a retroperitoneal organ which has both exocrine and 
endocrine functions. In man, it is divided into different parts like head, body, 
and tail, with the head of pancreas enclosed by the duodenum and the tail 
which abuts the spleen. The pancreatic cells are characterized into three 
distinct types of cells, namely the acinar cells, endocrine cells and the ductal 
cells. The acinar cells group to form acini which in turn form distinct lobules 
and secrete the digestive enzymes. The ductal cells form the pancreatic duct 
which joins with the common bile duct and opens into the second part of 
duodenum. The endocrine cells namely the Islets of Langerhans secrete 
hormones which help in regulation of glucose uptake, release and 
maintenance of serum glucose levels.3, 4, 5  
Fig 1: Anatomy of Pancreatic cells and the Ductal system 
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The blood supply of pancreas is derived from the Superior and 
Inferior Pancreaticoduodenal arteries and branches from the Splenic artery. 
Venous drainage is by Splenic vein, Superior mesenteric vein and the Portal 
veins. Lymphatics drain into the Splenic, Celiac and Superior mesenteric 
lymph nodes. 
 
Fig 2:  Blood Supply of Pancreas 
 
 
Pancreas plays an important role in digestion and absorption of food 
from the gut. It also regulates glucose homeostasis. Humoral control is by 
two hormones namely secretin and pancreozymin secreted by duodenum and 
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proximal jejunum. Secretin induces alkaline secretion and pancreozymin 
produces juice rich in amylase, lipase, and trypsinogen.  
ACUTE PANCREATITIS: 
 Acute pancreatitis is a common clinical condition encountered in our 
day to day surgical practice. Even though the volume of cases is high, acute 
pancreatitis poses a great challenge to the treating surgeon. 
In 1925, Lord Moynihan stated that, in connection with the abdominal 
viscera, the dreaded calamity is the Acute Pancreatitis. He substantiated his 
statement with the following features of acute pancreatitis „ Its sudden onset, 
unbearable agony and the mortality rate depending on its severity are the 
aspects of acute pancreatitis, which make it the most formidable to 
overcome‟.6 
Acute pancreatitis is an inflammation of the pancreatic tissue 
secondary to acinar cell necrosis. It occurs due to auto digestion by 
pancreatic enzymes.  
Epidemiology: 
As per data from the US, UK and Denmark, the incidence of acute 
pancreatitis varies between 4.8 to 24.2 cases per 100,000 population7 .Yet no 
prevalence data are available in India. 
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 Most patients develop a mild and a self-limited course, however 10% 
-20% of patients have a rapidly progressive course with prolonged length of 
hospital stay and significant morbidity and mortality. Mild pancreatitis is 
associated with a mortality rate of less than 1% but, it increases up to 10%- 
30% in severe pancreatitis.8 
CLASSIFICATION: 
 In 1992, the International Symposium in Atlanta was conducted on 
acute pancreatitis. According to it, acute pancreatitis was classified into mild 
and severe pancreatitis. Severe pancreatitis is diagnosed if there is any 
evidence of organ failure or local pancreatic complications.9 
 
Table 1: Atlanta classification of Acute Pancreatitis 
Classification  Clinical features  Morphologic findings 
Mild (“edematous 
pancreatitis”) 
Minimal organ 
dysfunction and 
uneventful 
recovery 
Interstitial edema and 
disseminated, usually 
microscopic, fatty tissue 
necrosis 
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Severe 
(“necrotizing 
pancreatitis”) 
Organ failure 
and/or local 
complications 
such as necrosis, 
abscess, or 
pseudo cyst 
Extensive fatty tissue 
necrosis and/or 
hemorrhagic necrosis 
involving both the 
pancreatic parenchyma 
and the extra pancreatic 
fatty tissue: 
development of pseudo 
cysts and abscesses 
 
Definition of organ failure by Atlanta 
 Shock–systolic pressure <90 mmHg 
 PaO2 ≤60 mmHg 
 Creatinine >2.0 mg/L after rehydration 
 Gastrointestinal bleeding >500 cc/24 h 
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OTHER DEFINITIONS: 
 Pancreatic necrosis: 
It is the non viable pancreatic tissue which can be focal or diffuse and is 
usually associated with peripancreatic fat necrosis. It can be infected or 
sterile.  
 
 Acute fluid collection: 
It is the fluid found inside or around the pancreas which does not have a 
definitive wall. It usually occurs in the earlier stages of acute pancreatitis in 
around 30% - 50% patients and resolves spontaneously. 
 Pancreatic pseudocyst: 
It is the fluid collection that remains for 4 - 6 weeks and is walled off by 
fibrous or granulation tissue. 
 Hemorrhagic pancreatitis: 
It is pancreatitis associated with hemoperitoneum which occurs due to 
erosion of pseudoaneurysm of the peripancreatic blood vessels. It can 
sometimes erode the retroperitoneal vessels resulting in acute hemorrhage 
which is an acute emergency. Management for this hemorrhage requires 
immediate angiographic embolisation or surgery. 
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PATHOPHYSIOLOGY: 
 Acute pancreatitis is a final result of abnormal pancreatic enzyme 
activation inside acinar cells. Trypsin which is derived from trypsinogen is 
the principal activator of all enzymes. Even normally a small proportion of 
trypsinogen gets activated spontaneously inside the acinar cells. But the 
various protective mechanisms present within pancreas wash out the 
activated trypsin so that there won‟t be any damage to the gland.  
These include: 
 Serine Protease Inhibitor Kazal type 1 (SPINK1) 
 Mesotrypsin 
 Enzyme Y 
 α1-antitrypsin 
 α2-macroglobulin 
In acute pancreatitis, Colocalisation is the first step as per 
Immunolocalisation studies. After a pancreatic injury, the above defensive 
mechanisms are overcome, zymogen granules and lysosome granules 
containing enzymes like cathepsin B colocalise inside the acinar cells 
resulting in intra acinar pancreatic enzyme activation.8 
 This induces auto digestion of the pancreatic parenchyma. In 
response, the acinar cells release pro-inflammatory cytokines such as TNF-α 
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(Tumour Necrosis Factor-α), IL-2, IL-1 and IL-6 .These mediators propagate 
the response both locally and systemically. 
 Neutrophils and macrophages are recruited in to the pancreatic 
parenchyma which cause the release of more TNF-α, IL-1, IL-6, reactive 
oxygen species, prostaglandins, platelet activating factor and leukotrienes. 
This further increases the permeability and damages the microcirculation of 
the pancreas.8 
 
Fig 3: Pathophysiology of Acute Pancreatitis 
The inflammatory cascade is self-limited in approximately 80% - 90% 
of patients. In small number of patients, there is massive release of 
inflammatory mediators into systemic circulation. Active neutrophils 
mediate acute lung injury and induce adult respiratory distress syndrome 
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(ARDS). Similarly it affects the kidneys and gut and progresses to Multi-
Organ Dysfunction Syndrome (MODS). 
Also Trypsin activates other pathways, such as complement, 
coagulation or fibrinolysis, extending the process outside the gland which is 
responsible for systemic manifestation of the disease. 
Genetic factors have also been implicated in pathogenesis of acute 
pancreatitis which is: 
 Cationic Trypsinogen gene (PRSS1) 
 Cystic Fibrosis Transmembrane Conductance Regulator Gene (CFTR) 
 Polymorphisms in SPINK1 
Fig 4: Events of Acute                            
                                                                                   Pancreatitis 
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ETIOLOGY: 
Gall stones and Alcohol are the most common (70% to 80%) causes of 
pancreatitis.8 Other etiological factors are as follows: 
Other causes 
  Shock 
Toxins 
 Scorpion venom, 
 Methyl alcohol, 
 Organophosphorous insecticides 
Drugs 
 Alpha- methyldopa 
 5-Aminosalicylate (mesalamine) 
 Azathioprine 
 Furosemide 
 Isoniazid 
 6- Mercaptopurine 
 Metronidazole 
 Dexamethasone 
 Trimethoprim/sulfamethoxazole 
Table 2: Etiological 
factors of Pancreatitis 
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 Antiretroviral drugs 
Metabolic- hypertriglyceridemia, 
Hypercalcemia 
Ductal obstruction-  
 Tumors, 
 Parasites, 
 Duodenal diverticula, 
 Annular pancreas, 
 Choledochocele 
Surgical procedure- ERCP 
Trauma 
Infection 
 Viral- Mumps, Coxsackie A, HIV, CMV 
 Bacterial- M.tuberculosis 
 Mycoplasma 
Hereditary/ familial/ genetic  
 
Biliary Pancreatitis: 
 It is one of the commonest etiologies of acute pancreatitis. Studies 
have shown that, episodes of acute pancreatitis are frequently preceded by 
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passage of stone into the duodenum. In about 90% of patients with stone 
induced pancreatitis, stones can be retrieved from their stools. 
 Various mechanisms have been proposed for biliary pancreatitis. 
 The theory proposed by Opie, termed as “Common channel 
theory”. The lodging of biliary stone in the common channel between the 
biliary tract and the pancreatic duct causes pancreatitis as a result of reflux 
of bile into the pancreatic duct. 
 Numerous studies have shown that the above theory may be not 
being as appropriate as the bile reflux is not sufficient to cause acute 
pancreatitis. This paves the way for the proposal of “Duct obstruction 
theory”, which states that the edema induced by the stones leads to the 
obstruction of the duct which in turn results in duct hypertension, triggering 
pancreatitis.8 
Alcohol Induced Pancreatitis:
8
 
 Although alcohol is the most frequent cause for chronic pancreatitis, it 
can also cause acute episodes. Various mechanisms have been proposed for 
pancreatitis induced by alcohol. 
 Ductal hypertension caused by alcohol induced spasm of 
sphincter of oddi. 
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 Free fatty acids produced by alcohol induced 
hypertriglyceridemia have a toxic effect on the pancreatic 
acinar cells. 
 Alcohol stimulates the production of free radicals within the 
pancreas which in turn injure the acinar cells. 
 Pancreatic ischaemia caused by alcohol induced 
microcirculation failure. 
 Alcohol stimulates the pancreatic acinar cells to produce 
protein-rich pancreatic juice, which has the following effects, 
-Formation of protein plug by the protein rich fluid,      
which causes duct obstruction. 
-The protective enzymes are overwhelmed resulting in 
auto-digestion of pancreas. 
Idiopathic Pancreatitis: 
 In spite of extensive studies, in about 20% of patients presenting with 
acute pancreatitis, no cause can be identified.  
The mechanisms proposed in such instances are: 
 Sludge or microcrystals in the gall bladder 
 Dysfunction of the sphincter leading to ductal hypertension 
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 Subclinical mutations in cystic fibrosis transmembrane                
regulator gene (CFTR gene) 
CLINICAL FEATURES:
8
 
Symptoms: 
 Abdominal pain is the most common symptom. the pain is usually 
 Epigastric radiating to the back 
 Constant severe pain 
 Typically relieved by leaning forward 
 Nausea and vomiting 
 Dyspnoea if there is associated pleural effusion 
Signs: 
 General examination reveals dehydration, tachycardia, tachypnoea, 
hypotension 
 Abdominal examination usually reveals severe epigastric tenderness 
associated with guarding and rigidity 
 Bowel sounds may be absent due to paralytic ileus 
 Retroperitoneal hemorrhage leading to bluish discoloration in 
 Umbilical area- Cullen‟s sign 
 Loin- Grey Turner‟s sign  
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 Groin- Fox‟s sign 
 
  Fig 5: A) Cullens sign B) Grey Turner’s sign 
  Fig 6: Fox’s sign 
 Pain or resistance in the zone where the head of pancreas is located (in 
the epigastrium, 6–7 cm above the umbilicus) - Korte's sign 
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 Pain with pressure under the xiphoid process - Kamenchik's sign 
 Tenderness on pressure at the Mayo-Robson's point - a point at the 
junction of the inner 2/3 and the outer 1/3 of the line that represents the 
bisection of the left upper abdominal quadrant. At this point the tail of 
pancreas is projected on the abdominal wall. 
 Thrombophlebitis in the legs 
INVESTIGATIONS: 
A. Blood investigations: 
 Serum Amylase: Most common serum marker used in 
diagnosis. It elevates within 2-12 hours of onset of symptoms and 
remains elevated for 3-6 days. In acute pancreatitis there is loss of cell 
to cell adhesions and so amylase gets access to vessels and is 
increased in serum. It has no prognostic value.  
Extrapancreatic sources of amylase need to be considered which are 
the salivary gland, lung, ovary, prostate. Other causes of 
hyperamylasemia also need to be considered like acute cholecystitis, 
intestinal ischaemia, hollow viscus perforation, intestinal obstruction 
and macroamylasemia. 
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 Serum Lipase: More specific for pancreas. Its limitation is that 
it remains elevated for 1 week, so it is not sensitive enough to detect 
complications. 
 Other investigations:  
i. Increased hemoglobin, hematocrit, Blood Urea Nitrogen 
(BUN) and creatinine due to hypovolemia. 
ii. Hypoalbumunemia secondary to fluid replacement with 
crystalloids 
iii. Hyperbilirubinemia which may be a cause or effect of 
acute pancreatitis 
iv. Hypocholeremic metabolic alkalosis secondary to 
excessive vomiting 
v. Hypocalcemia due to sequestration in pancreatic fat 
necrosis or associated hypoalbuminemia 
vi. Hyperglycemia due to associated diabetes mellitus, 
increased glucagon release, increased catecholamine release. 
B. Imaging Studies: 
 X-Ray Abdomen: Not specific for pancreatitis, but may show 
signs due to ileus 
1. Sentinel loop sign 
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2. Colon cut-off sign 
3. Renal halo sign 
 Ultrasonography abdomen: limited value in visualizing 
pancreas since it is usually obscured by bowel gas shadows. However, 
when detected following findings may be noted  
1. Bulky edematous pancreas 
2. Any associated biliary stone 
3. Dilated pancreatic duct 
4. Any fluid collections 
             
Fig 7: USG abdomen showing bulky   Fig 8: CT showing features of   
         hypo echoic pancreas         Acute pancreatitis 
 CECT Abdomen: it is the investigation of choice to diagnose acute 
pancreatitis and its complications. Following features may be noted 
1. Enlarged pancreas 
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2. Loss of peri pancreatic fat plane 
3. Areas of deceased density 
4. Localized fluid collection 
5. Detects pancreatic necrosis which is of great 
importance which is identified by non enhancement of 
> 30% or > 3cm of parenchyma of pancreas. 
CT is usually performed around 48hours after diagnosis as earlier done CT 
misses necrosis. The sensitivity of CECT to detect necrosis at 4 days is 
100%.10 
 MRI Abdomen: Can also be used in diagnosis and staging 
severity. Usually taken when CECT is contraindicated like in case of renal 
dysfunction or contrast allergy. Following table compares various imaging 
modalities used in acute pancreatitis10: 
Table 3: Comparison of various imaging modalities in acute pancreatitis 
Imaging Technique Effectiveness 
CECT abdomen 78 % sensitivity and 86% 
specificity for severe acute 
pancreatitis 
Endoscopic USG 100 % sensitivity and 91 % 
specificity for gallstones 
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 81 to 100 % sensitivity for 
detecting CBD stones 
MRCP 98 % negative predictive value 
and 94% positive predictive value 
for bile duct stones 
 As accurate as CECT in 
predicting severity of pancreatitis 
and identifying pancreatic 
necrosis. 
MRI  83% sensitivity and 91% 
specificity for severe acute 
pancreatitis 
USG abdomen 87 to 98% sensitivity for the 
detection of gallstones. 
 
DIAGNOSIS: 
Diagnosing acute pancreatitis requires clinical, serological and imaging 
correlation. Various serum markers are used in the diagnosis and prognosis 
of acute pancreatitis. Some of them have been summarized in the following 
table.11  
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 Table 4: Various Serum markers in Acute Pancreatitis 
Laboratory 
Test 
Time of 
onset 
(Hours) 
Purpose Clinical 
observation / 
limitations 
Alanine 
transaminase 
12 to 24 Diagnosis 
and 
etiology 
Associated 
with gallstone 
pancreatitis; 
threefold 
elevation or 
greater in the 
presence of 
acute 
pancreatitis 
has a positive 
predictive 
value of 95 
percent in 
diagnosing 
acute 
gallstone 
pancreatitis 
Amylase 2 to 12 Diagnosis Most accurate 
when at least 
twice the 
upper limit of 
normal; 
amylase levels 
and sensitivity 
decrease with 
time from 
onset of 
symptoms 
C-reactive 
protein 
24 to 48 Predictive 
of severity 
Late marker; 
high levels 
associated 
with 
pancreatic 
necrosis 
Interleukin-6 18 to 48 Predictive 
of severity  
Early 
indication of 
severity 
Interleukin-8 12 to 24 Predictive 
of severity 
Early 
indication of 
severity 
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Lipase 4 to 8 Diagnosis Increased 
sensitivity in 
alcohol-
induced 
pancreatitis; 
more specific 
and sensitive 
than amylase 
for detecting 
acute 
pancreatitis 
Phospholipase 
A2 
24 Predictive 
of severity 
Associated 
with 
development 
of pancreatic 
necrosis and 
pulmonary 
failure 
Procalcitonin  24 to 36 Predictive 
of severity 
Early 
detection of 
severity; high 
concentrations 
in infected 
necrosis 
Trypsinogen 
activation 
peptide 
Within 
few hours 
Diagnosis 
and 
predictive 
of severity 
Early marker 
for acute 
pancreatitis 
and close 
correlation to 
severity 
 
The Atlanta symposium devised certain criteria for the diagnosis of 
acute pancreatitis. According to it, any two of the following three features is 
required for diagnosis: 9 
 Abdominal pain consistent with acute pancreatitis, i.e., severe 
and persistent epigastric pain, acute in onset, radiating to the back 
 Serum amylase or lipase: three or more times the normal limit 
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 CECT (Contrast Enhanced Computerized Tomography) 
findings characteristic with acute pancreatitis and less commonly with MRI 
or Ultrasonography of abdomen 
DIFFERENTIAL DIAGNOSIS: 
 Biliary colic/ Acute cholecystitis 
 Perforated hollow viscus 
 Mesenteric ischaemia/ infarct 
 Inferior wall myocardial infarction 
 Closed loop intestinal obstruction 
 Dissecting aortic aneurysm 
 
COMPLICATIONS OF PANCREATITIS: 
 Local: 
 Fluid collections 
 Pancreatic Ascites/ Pleural effusion 
 Pseudocyst 
 Pancreatic necrosis 
 Pancreatic abscess 
 Pseudoaneurysm/hemorrhage 
 Splenic vein rupture 
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 Portal vein rupture 
 Gastrointestinal bleeding 
 Postnecrosectomy bleeding 
 Splenic infarction 
 Enteric fistula 
 Smoldering pancreatitis: 
In this entity, despite adequate supportive therapy, the pain persists for 
2-3 weeks or more with persistent hyperamylasemia. The cause may 
be varied and includes any of the causes of acute pancreatitis. Imaging 
shows significant pancreatic injury suggesting a functional obstruction 
to the pancreatic duct secondary to edema or spasm. Transpapillary 
stenting relieves the symptoms. 
 Regional: 
 Venous thrombosis 
 Paralytic ileus 
 Intestinal obstruction 
 Intestinal ischaemia 
 Cholestasis 
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 Systemic: 
 SIRS 
 MODS 
 ARDS 
 Renal failure 
 Cardiovascular complications 
 Hypocalcemia 
 Hyperglycemia 
 Disseminated Intravascular Coagulation 
 Protein malnutrition 
 Encephalopathy 
 Fat necrosis (subcutaneous nodules) 
 Retinopathy 
 Death  
 
SEVERITY SCORING SYSTEMS: 
 As there is high morbidity and mortality associated with severe acute 
pancreatitis, many scoring systems have been formulated to stratify the risk 
of developing severe pancreatitis. All the scoring systems have been devised 
keeping the Atlanta‟s classification as a standard. The Clinical scoring 
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system and certain laboratory tests are the most common methods of 
assessing the prognosis in acute pancreatitis.12The most commonly used 
systems are the Ranson‟s criteria, The Modified Glascow system (Imrie 
Scoring), APACHE II scoring system. 
 Ranson‟s criteria were devised in 1974 which consists of 11 
parameters which are derived from patients at the time of admission and at 
48 hours. Severe pancreatitis is defined if 3 or more of its parameters are 
fulfilled. The disadvantage of this criterion is that it can predict only at the 
end of 48 hours. Also it has a low positive predictive value (50%) but a high 
negative predictive value (90%).  
Hence, it is mainly used to rule out a severe disease. The same is true 
for Imrie score.8 
Table 5: Ranson’s criteria (Non-Gallstone Pancreatitis) 
At admission 
 Age in years > 55 years 
 Leucocyte count > 16000 cells/mm3 
 Blood glucose > 10 mmol/L (> 200 mg/dL) 
 Serum AST > 250 IU/L 
 Serum LDH > 350 IU/L 
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At 48 hours 
 Calcium (serum calcium < 8.0 mg/dL) 
 Hematocrit fall >10mmol/l 
 Oxygen (hypoxemia PO2 < 60 mmHg) 
 BUN increased by 5 or more mg/dL after IV fluid hydration 
 Base deficit (negative base excess) > 4 mEq/L 
 Sequestration of fluids > 6 L 
 
Table 6: Ranson’s criteria (Gallstone Pancreatitis) 
At admission 
 Age in years > 70 years 
 Leucocyte count > 18000 cells/mm3 
 Blood glucose > 220 mg/dL) 
 Serum AST > 250 U/100mL 
 Serum LDH > 400 IU/L 
At 48 hours 
 Calcium (serum calcium < 8.0 mg/dL) 
 Hematocrit fall >10mmol/l 
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BUN increased by 2 or more mg/dL after IV fluid hydration 
 Base deficit (negative base excess) > 5 mEq/L 
 Sequestration of fluids > 4 L 
 
Interpretation: 
 Score <  3- Mild Pancreatitis 
 Score 4 to 6- Moderate Pancreatitis 
 Score > 7- Severe Pancreatitis 
 
Table 7: Modified Glascow index (Imrie score) 
The Glasgow criteria are valid for both gallstone and alcohol induced 
pancreatitis 
• Age >55 years old 
• PaO2 < 8kPa 
• Neutrophilia – Leucocyte count >15x10(9)/L 
• Calcium < 2mmol/L 
• Urea > 16mmol/L 
•AST >200 IU/L; LDH > 600 IU/L 
• Serum Albumin < 3.2g/dl 
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• Blood glucose >180mg/dl 
Interpretation: 
Scores 3 or more it indicates severe pancreatitis 
 
The Acute Physiology and Chronic Health Examination (APACHE) II 
is one of the most widely used systems for early risk stratification in acute 
pancreatitis. It is based on patient‟s age, previous health status and 12 
routine physiological parameters. An APACHE II score of 8 or more 
indicates severe disease. The main advantage of this system is that it can be 
used at the time of admission and at any time. However, its major drawback 
is that it needs multiple parameters and an online calculator for interpreting 
the severity. 
 There are modifications to this system which are: 
 APACHE 3- here 5 additional criteria are included to increase the 
accuracy.13 
 APACHE O- here clinical assessment of obesity is also included 
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Table 8: APACHE II Score 
I. Physiologic variable 
 Rectal temperature (ºC) 
 Mean arterial pressure (MAP) in mm Hg 
 Heart rate in beats/min 
 Respiratory rate in breaths/min 
 PaO2 in mm Hg 
 Arterial pH 
 Serum sodium in mEq/l 
 Serum potassium in mEq/l 
 Serum creatinine in mg/dl 
 Hematocrit in percentage 
WBC count/ mm3 
 Glasgow Coma Score 
The total acute physiology score = sum of above points 
II. Age Points 
Less than 44 years (0 point) 
45-54 years (2 points) 
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55-64 years (3 points) 
65-74 years (5 points) 
≥75 years (6 points) 
III. Chronic Health Points – points are assigned as below if the patient 
gives a history of severe organ insufficiency or is immunocompromised: 
For nonoperative or emergency postoperative patients (5Points) 
For elective postoperative patients (2 points) 
The APACHE II score = I+II+III 
Interpretation: 
A score of > 8 is considered as severe pancreatitis 
 
CT has become routinely used in the prediction and determination of 
disease severity. Balthazar and his associates established the CT severity 
index. However, using CT alone was associated with relatively high false-
positive rates. 
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Table 9: CT Severity Index 
Balthazar Grades 
Grade A: Normal pancreas consistent with mild pancreatitis (0 points) 
Grade B: Focal or diffuse enlargement of the gland without peripancreatic 
inflammation (1 point) 
Grade C: Peripancreatic inflammation (2 points) 
Grade D: Peripancreatic inflammation with single fluid collection (3 points) 
Grade E: Peripancreatic inflammation with two or more peripancreatic fluid 
collections or gas in the pancreas or retro peritoneum (4 points) 
Necrosis score: 
Absence of necrosis (0 point) 
Up to 33% necrosis (2 points) 
33% to 50% necrosis (4 points) 
 >50% necrosis (6 points) 
CTSI = Balthazar Grade Score + Necrosis Score 
Interpretation: 
0-3 points: Mild pancreatitis 
4-6 points: Moderate pancreatitis 
7-10 points: Severe pancreatitis 
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BISAP (Bedside Index for Severity in Acute Pancreatitis) score is a 
simple tool which comprises of 5 parameters. A score of more than 3 is 
associated with higher risk. 
Table 10: BISAP score 
• Blood urea nitrogen more than 25 mg/dL, 
• Mental status impairment, 
•SIRS (Systemic inflammatory response syndrome), defined as two or more 
of the following 
 - Temperature < 36 or > 38° C 
 - Respiratory rate > 20 breaths/min or PaCO2 < 32 mmHg 
 - Pulse rate > 90 beats/min 
 - WBC counts < 4000 or > 12,000 cells/ mm3 or > 10% immature               
bands 
• More than 60 years of age, and/or 
• Pleural effusion 
 
Interpretation: 
A Score of more than 3 is associated with 7 to 12 fold increase in risk of 
organ failure. 
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Other biochemical markers include as follows: 
 C - reactive protein (CRP): 
CRP is an acute-phase reactant produced by the liver and is used 
extensively as a marker of severe pancreatitis. However it is non 
specific as its levels rise in most inflammatory conditions. The 
limitation with CRP is that it can be measured only after 48hrs as it 
lacks sensitivity before 48hrs. 
 Polymorphonuclear Leukocyte Elastase:  
Polymorphonuclear leukocyte elastase rises very early, even before 
CRP, in acute pancreatitis. High levels have been reported to 
differentiate severe from mild disease. 
 Phospholipase A2 (PLA2): 
PLA2 is involved in the release of prostaglandins from cell 
membranes and degrades surfactant in the lung. It plays a role in the 
pulmonary dysfunction associated with acute pancreatitis. Levels of 
catalytic type II PLA2 are used to differentiate between mild and 
severe disease within 24 hours of admission 
 Urinary Trypsinogen Activation Peptide (TAP): 
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Urinary TAP may serve as an early predictor of severity in patients 
with acute pancreatitis. Elevated urinary TAP >30 nmol/L correlates 
with disease severity. The test can be applied within 12 hours of 
admission. The positive predictive value of an elevated TAP is 80% 
and the negative predictive value approaches 100%. 
 Procalcitonin:  
This propeptide is another acute-phase reactant that has been 
shown to differentiate mild from severe acute pancreatitis within the 
first 24 hours after symptom onset. A serum strip test that has a 
sensitivity of 86% and a specificity of 95% in detecting organ failure 
has been developed. It has a drawback that it is not available at all 
centres and is expensive. 
 Interleukin-6 (IL-6):  
IL-6 is an acute-phase reactant cytokine that is produced by a 
variety of cells and induces hepatic synthesis of CRP. Several studies 
have shown that it is a reasonably good marker to differentiate mild 
from severe disease, but the test is not readily available in all centres 
and is very expensive. 
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 Serum Amyloid A:  
Serum amyloid A is another early acute-phase reactant that is 
synthesized in the liver and is associated with the extent of tissue 
inflammation. Studies have demonstrated that the level of this serum 
protein can differentiate mild from severe disease. However, it is 
expensive and not available in peripheral centres. 
It can be noticed that the limitation with other parameters is that 
they are very costly and not easily available. 
 LDH (Lactate dehydrogenase) : 
Chen and coworkers 63 found that in 42 patients with acute 
pancreatitis, serum LDH activity was significantly higher in severe 
than in mild attacks. Moreover, by evaluating the distribution of the 
five known LDH isoenzymes, they found that LDH-4 and LDH-5 
were the only isoenzymes increased during the disease and that LDH-
4 was the only isoform that could differentiate between severe and 
mild attacks. However, because the predominant pancreatic 
isoenzymes are LDH-2 and LDH-3, these results showed that the 
pancreas was not the major source of LDH. 
Lactate dehydrogenase (LDH) has been reported to be a 
sensitive indicator of pancreatic necrosis. In patients with biliary 
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pancreatitis, however, liver enzymes are generally elevated early in 
the course of the disease because of acute inflammatory liver cell 
injury caused by ampullary stones impacted during their transpapillary 
passage. 
Accordingly, the identification of pancreatic necrosis using the 
initial high LDH activity as an indicator of necrosis may not be 
accurate. 
  In a study by Isogai and co workers it was proved that an 
elevation of the ratio of LDH to aspartate aminotransferase (AST) 
(LDH/AST) would better reflect pancreatic necrosis in biliary 
pancreatitis. 
On realizing the importance of acute pancreatitis, extensive studies 
were conducted by numerous medical practitioners regarding evaluation of 
the severity of acute pancreatitis and designed various scoring systems. They 
also even compared these scoring systems with one another to find out a 
single best possible way to predict the severity of acute pancreatitis. The 
following are few examples of such studies. 
In 2012 (April), Thomas L Bollen et al compared the radiological and 
clinical scoring systems in acute pancreatitis in his study and came to a 
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conclusion that routine CT abdomen, on admission is not recommended in a 
case of acute pancreatitis for assessing its severity.14 
In 2012 (March), Rawad Mounzer et al, in his study, compared all 
clinical scoring systems which are currently in use to predict organ failure, 
which is one of the grave catastrophes of acute pancreatitis. He finally came 
to a conclusion that all scoring systems have reasonable accuracy in 
predicting persistent organ failure, but the Glascow score was found to be 
the best.15  
In 2012 (Feb), Fabre et al compared several scoring systems in 
paediatric age group presenting with acute pancreatitis. He studied the 
sensitivity and specificity of each score and compared with one another and 
he found that the best parameter to assess the severity of acute pancreatitis in 
paediatric population is CT severity score.16 
In 2011 (September), Zhang WW et al, on comparing the clinical 
scoring and CT severity scoring, he found that CT has superior role than 
clinical scoring in depicting the extra-pancreatic inflammation spread in 
cases of acute pancreatitis and he also found that CT severity index has good 
correlation with APACHE II and Ranson‟s scores.17 
In 2011 (May), Su Mi Woo et al did an extensive study about serum 
Procalcitonin in predicting the severity of acute pancreatitis and he 
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compared the same with other severity indices. He inferred that, serum 
Procalcitonin was a simple promising biomarker as its accuracy in predicting 
the severity of acute pancreatitis, is similar to other scoring systems such as 
APACHE II score.18 
In 2011 (Jan), Chavarri Herbozo et al conducted a study about 
hemoconcentration as an early predictor of severity in acute pancreatitis and 
compared it with other scores such as APACHE II and Ranson‟s scores. He 
found that hemoconcentration as a single parameter, is not much useful in 
predicting the severity in patients with acute pancreatitis.19 
In 2007, Ekrem et al conducted a study and found out definite relation 
between the elevation of the following parameters and mortality and 
morbidity in patients presenting with acute pancreatitis. The parameters 
include CRP, BUN, LDH, CT severity index and APACHE score.20 
In 2006, Yuk Pang et al, in his study compared Ranson‟s score with 
APACHE scores in 101 patients of acute pancreatitis and concluded that 
APACHE II score is more accurate than that of Ranson‟s score in predicting 
the severity of acute pancreatitis.21 
In 2005, Ting-Kai Leung et al conducted a study which spanned over 
five years. In his study, he compared Ranson‟s and APACHE II scores with 
that of helical CT in predicting the severity of acute pancreatitis and he 
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found that the former is inferior to Balthazar computed tomography severity 
index in predicting acute pancreatitis outcome.22 
 The WBC count is a well known marker of infection and 
inflammation, and is part of many scoring systems in acute pancreatitis 
including Ranson, Imrie and APACHE II. The total WBC count comprises 
of neutrophils and lymphocytes both of which are individually markers of 
inflammation. It has been identified that following an insult, there is 
neutrophilia and lymphocytopenia which occurs within 4 to 8 hours as a 
response to severe infection, surgical stress, systemic inflammation and 
septic shock.  
As per Mahidhara and Billiar, the reason for neutrophilia is due to 
delay in apoptosis of neutrophils, demargination of neutrophils from 
endothelium and as an effect of growth factors.  
Hotchkiss et al, Ayala et al and many others have observed apoptosis 
of lymphocytes which resulted in lymphocytopenia. Menges et al supported 
this with his flow cytometric assays which showed a decrease in T4- helper 
lymphocytes following multiple trauma and hence responsible for SIRS and 
MODS. It has been stated that lymphocytopenia not only indicates the 
severity of the stressful condition, but also reflects the efficacy and 
adaptability of the immune system. 
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The response of the inflammatory/ immune system to stress can be 
easily assessed by the ratio of neutrophil count (in %) to lymphocyte count 
(in %). As per a study by Zahorec et al the severity of insult, severity of 
clinical status and clinical outcome, was found to correlate nicely with 
neutrophil/lymphocyte ratio with regard to APACHE II and SOFA scoring 
systems. He has suggested that when the differential counts of WBC were 
serially monitored, it provided information about the body‟s immunological 
response to stress in critically ill patients.23  
In Acute pancreatitis, neutrophils propagate inflammation and tissue 
destruction via activation of a cascade of inflammatory cytokines (IL-6, IL-
8, and TNF-α), proteolytic enzymes (myeloperoxidase, elastase, collagenase, 
and β - glucoronidase), and oxygen free radicals. An increase in neutrophil 
numbers corresponds with the development of SIRS and progression to 
MODS, which are hallmarks of Severe Acute pancreatitis. This Uncontrolled 
inflammation is thought to precipitate lymphopenia by lymphocyte 
redistribution and accelerated apoptosis, and lymphopenia.24 
It is the divergence of these two components of the WBC counts 
namely neutrophilia and lymphopenia that led to the proposal of assessing 
the NLR as a single and more accurate predictive factor than either 
component alone. This has been assessed by Suppiah A et al, Azab et al and 
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Vedat Goral et al and they have uniformly accepted that the NLR is a simple 
indicator of severity in patients presenting with acute pancreatitis.24, 33, 34 
TREATMENT:
8
  
           Treatment of acute pancreatitis depends on the severity of 
pancreatitis. Most of the cases of pancreatitis are managed conservatively 
except in cases of acute severe necrotizing pancreatitis and complications 
which warrants surgical intervention. 
 Aggressive fluid resuscitation, control of pain, strict monitoring of 
hemodynamic status, nutritional support, and surveillance for complications 
are important in management of patients with acute pancreatitis. 
The cornerstone of the treatment of pancreatitis is aggressive volume 
repletion using crystalloid solution. The rate of administration should be 
individualized and adjusted based on age, co morbidities, vital signs, mental 
status, skin turgor and urine output. 
 Patients require pulse oximetry because one of the most common 
systemic complications is hypoxemia caused by acute lung injury. They 
should receive supplementary oxygen to maintain arterial saturation above 
95%. 
 It is also essential to provide adequate analgesia. Narcotics are 
usually the preferred group of analgesics. 
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 Nutritional support is vital in the treatment of acute pancreatitis. It 
has been shown that enteral nutrition has many benefits over total parenteral 
nutrition in severe acute pancreatitis. However, a meta-analysis showed that 
total enteral nutrition has no better advantage over total parenteral nutrition 
with respect to outcome.25  
 Role of antibiotics in pancreatitis is controversial. Recent meta-
analyses have proven that prophylactic antibiotics do not decrease the 
frequency of surgical interventions, infected necrosis, or mortality in patients 
with severe pancreatitis. In addition, they are associated with gram positive 
cocci and candidal infections. Further, some meta- analyses conclude that 
the use of antibiotics prophylactically can reduce the infection, surgical rates 
and sepsis and in turn mortality. Thus, the use of prophylactic antibiotics for 
necrotizing pancreatitis must be weighed carefully with the benefits and 
risks.25  
The role of Somatostatins and octreotide in acute pancreatitis is that, 
they inhibit both the basal and stimulated pancreatic secretion. They also 
stimulate reticuloendothelial system activity, modulate the cytokine cascade 
and are cytoprotective with respect to the pancreas.  
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These effects of somatostatin and octreotide suggest that both drugs 
may be useful either in the treatment of pancreatic disorders, or in 
preventing acute pancreatitis.  
   The role of surgery in acute pancreatitis includes debridement of the 
necrotic material in infected necrotizing pancreatitis and in clinically 
deteriorating patients with sterile necrosis. The timing of surgery is usually 
within two weeks of the onset of symptoms.  
 
 The indications for surgical intervention in necrotizing pancreatitis 
are: 
 Diagnostic uncertainty 
 Intra-abdominal catastrophe unrelated to necrotizing 
           pancreatitis 
 Infected necrosis documented by FNA or extraluminal 
gas on CT 
 Severe sterile necrosis 
 Symptomatic organized pancreatic necrosis 
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Surgical options for infected necrosis include: 
 Minimally invasive management - necrosectomy 
 
 Conventional management - necrosectomy with simple 
drainage 
o Closed lavage of the debrided cavity, 
o Closed management - necrosectomy with closed 
continuous postoperative lavage 
o Open management - necrosectomy with planned staged 
reoperations at definitive intervals with repeated lavage. 
 In case of Gall stone induced pancreatitis, early laparoscopic 
cholecystectomy is indicated in mild cases where cholecystetomy is done 
during the initial admission itself as it is a safe procedure and reduces 
recurrence. In severe case however, cholecystectomy is planned only after 6 
weeks in order to reduce the stay. 
 The use of ERCP with sphincterotomy in pancreatitis is only 
indicated in:  
 Severe acute biliary pancreatitis 
 Those who develop cholangitis, 
 Those with persistent bile duct obstruction and  
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 In older patients unfit for surgery.8 
But the disadvantages associated with ERCP are: 
 ERCP itself can precipitate pancreatitis and it can introduce 
infection to sterile pancreatitis 
 The risk of bleeding is present 
Role of Pancreatic resection in acute pancreatitis: 
Ductal necrosis can result in the entity called disconnected duct 
syndrome, most commonly involving the mid pancreatic body along with the 
ductal epithelium. Disconnected pancreatic duct is an anatomic situation 
where there is a lack of ductal continuity between viable secreting pancreatic 
tissue and the gastrointestinal tract .The isolated viable pancreatic segment 
continues to have an exocrine output that is not drained into the bowel. The 
resultant fistula and inflammatory collections are persistent and are unlikely 
to resolve with conservative drainage measures, mandating surgical 
treatment. 
The criteria for diagnosing disconnected duct syndrome include: 
i) ERCP evidence of main pancreatic duct cut-off or discontinuity 
with inability to access or cannulate the upstream pancreatic duct; 
ii) CT evidence of viable pancreatic tissue upstream from the 
pancreatic duct cut-off or discontinuity and 
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iii) A non healing pancreatic fistula, pseudocyst or fluid collection 
despite a course of conservative medical management. 
Pancreatic duct leaks and fistulas occur at times in acute necrotizing 
pancreatitis. The damage to the pancreatic ductal system allows pancreatic 
juice to leak from the gland. Sudden development of hypocalcemia or a 
rapid increase in retroperitoneal fluid on CT scan is suggestive of this 
condition.  
Ductal disruption following acute pancreatitis can result in pancreatic 
fluid collection or pseudocyst, pleural effusion, pancreatic ascites, 
pancreaticocutaneous fistulas and severe pancreatic necrosis. Main 
pancreatic ductal disruption causes continuous enzymatic insult to the 
pancreas and a disconnected gland syndrome. 
Ductal disruption can be associated with a pancreatico-cutaneous 
fistula, especially after surgical necrosectomy or percutaneous drainage. If 
surgical necrosectomy is mandated in severe cases with infected necrosis, 
the percutaneous drainage of fluid collections should be avoided because it 
transforms a collection easily accessible to endoscopic drainage into a 
permanent fistula with a high rate of relapse, when the percutaneous drain is 
removed. 
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Refractory cases require surgery. In 1963, Watts described survival of 
a patient with pancreatitis who had been treated by total pancreatectomy 
approximately 48 hours after onset of symptoms.  
 If the persistent leak is present in the tail of the gland, a distal 
pancreatectomy is preferred. 
 If the leak is in the head of the gland, a Whipple procedure is 
the operation of choice.26, 27, 28 
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Fig 9: Algorithm for management of Acute Pancreatitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosed acute pancreatitis 
Classify severity 
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Managed in intensive 
care, antibiotics 
CT within 24hrs of 
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Gall stones 
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sepsis 
 
Aaa No improvement/worsening 
ERCP 
sphincterotomy 
<72 hrs 
Gall stone 
eradication 
FNA of pancreas. If infected consider changing antibiotics and performing 
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Present 
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MATERIALS AND METHODS 
 
 This prospective study was conducted in Department of General 
Surgery, Government Royapettah Hospital from January 2013 to July 2013 
after obtaining permission from the Institution‟s Research and Ethical 
committee. 
SOURCE OF DATA: 
         The study was conducted on sequential admission of 100 patients 
diagnosed with acute pancreatitis in Government Royapettah Hospital. 
METHOD OF COLLECTION OF DATA: 
 Patients with acute pancreatitis were diagnosed as per Atlanta 
symposium which is any two of the three findings: 
 Abdominal pain consistent with acute pancreatitis, i.e., 
severe and persistent epigastric pain, acute in onset, radiating to 
the back 
 Serum amylase or lipase: three or more times the normal 
limit ( in our laboratory normal value of Sr. amylase- 50 – 150 
SU/dL. 
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 CECT (Contrast Enhanced Computerized Tomography) 
findings characteristic with acute pancreatitis and less 
commonly with MRI or Ultrasonography of abdomen 
 Informed consent was obtained from patients for including 
them in my study 
 Blood samples were taken at the time of admission and sent for 
Serum Amylase, Sr. urea, Sr. creatinine and liver function test 
analysis 
 Similarly, Samples were sent for total WBC count and 
differential count 
 At the time of admission 
 At 24hrs   
 At 48hrs  
 Neutrophilic lymphocytic ratio (NLR) was calculated which is 
the ratio of the Absolute Neutrophil count (in %) and Absolute 
Lymphocyte count (in %).  
 Appropriate tests were conducted like Sr. Creatinine, Blood 
Pressure monitoring and Spo2 as and when needed to look for features 
of organ failure. 
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 NLR values were correlated with the severity of pancreatitis as 
per Atlanta classification.  
INCLUSION CRITERIA:  
 All cases of acute pancreatitis admitted in our hospital from 
December 2012 to July 2013. 
EXCLUSION CRITERIA: 
 Patients with chronic pancreatitis 
 
METHOD OF STATISTICAL ANALYSIS: 
  The NLR for day 0, day1 and day 2 for mild pancreatitis and severe 
pancreatitis were analyzed using independent sample t test. A „p‟ value of < 
0.05 is indicated as statistically significant. 
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RESULTS 
I)  DEMOGRAPHIC DATA: 
   Of the admissions that were between December 2012 to July 2013, 
100 patients with acute pancreatitis details were accumulated and results 
analyzed as follows.  
   Of the 100 patients, 80 patients had mild pancreatitis and 20 patients 
developed severe pancreatitis. Of the severe pancreatitis patients, 6 patients 
developed organ failure, 4 patients developed pseudocyst, 2 developed 
pancreatic abscess and 8 patients had organ failure. Of these patients, 4 of 
them died. 
 
Chart 1: Mild vs. Severe Pancreatitis 
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Chart 2: Presentation of Severe pancreatitis 
 
A. Age: 
Among the 100 patients it was noted that pancreatitis occurred more 
in the age group of 31-40 years. It can be seen that on calculating the 
percentage of severe pancreatitis among each group, it was highest in the 51-
60yrs age group (50%).  
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Chart 3: Age distribution  
Among 100 patients, on comparing the sex distribution, in my study 
only 4 patients in acute pancreatitis were females.  
 
Chart 4: Sex Distribution 
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II) CLINICAL DATA: 
The Total WBC count was significantly increased in severe 
pancreatitis group. The differential count were individually analyzed which 
is summarized as follows 
A. Neutrophil count:: 
It was found that in my study the neutrophil count in both mild and 
severe pancreatitis was high on the day of admission. Over the next 48 
hours, the neutrophil counts decreased in mild pancreatitis whereas, in 
severe pancreatitis group, the neutrophil count was persistently high.
 
Chart 5: Trend of Neutrophil Count 
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B. Lymphocyte count: 
Both in mild and severe pancreatitis, the lymphocyte count were 
suppressed. Over, the next 48 hours, the counts started to rise in mild 
pancreatitis group whereas it started to fall further in severe 
pancreatitis group. 
Chart 6: Trend of Lymphocyte Count                    
 
C. Neutrophilic lymphocytic ratio (NLR): 
As there was a change in the trend of neutrophils and lymphocytes 
over 48 hours, the NLR calculated over the 48 hours was analyzed 
and tabulated using independent sample t test. It was found that there 
was a statistically significant difference (p< 0.05) between the mild 
and severe pancreatitis group. The NLR was found to be significantly 
higher in severe pancreatitis group than the mild pancreatitis group. It 
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seemed to return to slightly fall in mild pancreatitis group, but it was 
persistently high and increasing in severe pancreatitis group. 
  Chart 7: Trend of NLR                 
 
Group Statistics 
 Atlanta 
classfn N Mean 
Std. 
Deviation 
Std. Error 
Mean 
day0 Mild 80 4.3849 1.44457 .16253 
Severe 20 8.2075 3.81838 .85382 
 
Group Statistics 
 
Atlanta 
classfn N Mean 
Std. 
Deviation 
Std. Error 
Mean 
day1 Mild  80 5.0749 1.92036 .21606 
Severe 20 9.0665 3.39489 .75912 
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Group Statistics 
 Atlanta 
classfn N Mean 
Std. 
Deviation 
Std. Error 
Mean 
day2 Mild 80 4.5182 1.86058 .20933 
Severe 20 10.8925 3.96859 .88740 
 
 
NLR p value 95% 
confidence 
interval 
Day 0 .000 5.63-2.01 
Day 1 .000 5.62-2.35 
Day 2 .000 8.26-4.47 
 
On applying the levene‟s test, it was found that the NLR was 
significantly increased in severe pancreatitis was significantly higher 
in severe pancreatitis group than the mild pancreatitis group. 
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DISCUSSION 
 In this study on 100 patients, acute pancreatitis was more 
predominant among Males (96%) than females (4%). This was 
similar to a study done by Rithin et al. in which pancreatitis was 
common among males.29 Also it is comparable to a study by Savio 
G Barreto et al, where their male: female ratio was 96.1%: 3.9%.30 
This observation may be due to the reason that alcohol 
consumption is more common among males in a developing 
country like India. 
 In my study, most of the patients who presented with acute 
pancreatitis belonged to 31-40 yrs age group. The mean age was 
around 38.3% compared to the study by Rithin et al in which the 
mean age was 40.9%.29 Similarly; mean age was 40yrs in a study 
by Savio G Barreto et al.30 
 In my study, the most common etiology was alcohol which 
was around 98% as compared to study by Savio G Barreto et al, 
where alcohol was the causative agent in 92.6% and gallstones in 
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19%.30 In another study by Kimmo et al, alcohol was accounted to 
79 % and gall stones to 13%.31   
 Of the 100 patients, 80% of them had mild pancreatitis and 
20% had severe pancreatitis as compared to study by Savio G 
Barreto et al, 67 % had mild and 33% had severe disease.30 My 
study seems comparable to the rate of incidence of mild and severe 
pancreatitis as per Atlanta symposium, in which the rate of mild 
pancreatitis is 70-80 % and 20-30 % in severe pancreatitis patients. 
 In my study, mortality rate 4% as compared to a mortality 
rate of 12% by Savio G Barreto et al.30 
 In my study I also noticed that, serum amylase was elevated 
(≥ 3times the normal) in only 37 patients while it was < 3 times the 
normal in 63 patients. This was in contrast to the diagnostic criteria 
proposed by the Atlanta. When analyzed, there were studies which 
showed lower levels of amylase in patients with acute pancreatitis 
and severe destruction of the pancreas. Winslet et at reported that 
patients with low enzyme levels more frequently had associated 
pancreatic necrosis. Lankisch P G et al in his study suggested that 
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we should not depend on elevated enzyme levels of >3n for 
diagnosis. Also they reported that it was especially true in 
pancreatitis caused by alcohol, where the amylase level was lower 
at the time of admission. As alcohol induced pancreatitis was the 
major cause in my study group the lower amylase values may be 
attributable to it.32 
 The primary finding in my study is that the Neutrophilic 
Lymphocytic Ratio (NLR) was elevated in patients presenting with 
acute pancreatitis. The NLR was increased when compared to the 
normal (2.63).34 
 The WBC count is a marker of infection and inflammation. It 
is a part of many scoring systems used to prognosticate acute 
pancreatitis. The two important components of WBC are the 
neutrophils and lymphocytes. In acute pancreatitis inflammatory 
cytokines like TNF-α are responsible for recruitment of neutrophils 
and macrophages into the pancreatic tissue. The neutrophils in turn 
propagate inflammation and tissue destruction through proteolytic 
enzymes (myeloperoxidase, elastase, collagenase and β-
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glucoronidase), cytokines (IL6, IL8, TNF-α) and oxygen free 
radicles. As the severity of pancreatitis increases, there is 
progression to Systemic Inflammatory Response (SIRS) and Multi 
Organ Dysfunction Syndrome (MODS) and this corresponds with 
the increase in neutrophil numbers.  
 This was clearly elicited in my study where the neutrophil 
count progressively increased in severe pancreatitis group, where 
there was progression to SIRS. In contrast, in mild pancreatitis, as 
the disease severity decreased, the neutrophil count also started to 
decline toward normalcy. 
 Lymphocyte numbers increase following the initial stress and 
mediate the subsequent inflammatory response. The previous view 
is that neutrophilia is the primary cause of an elevated NLR, SIRS 
and poor prognosis, while lymphocyte count remains constant. 
However in my study, as per (chart 6) there was lymphopenia 
within 24hrs of admission which was persistent in severe 
pancreatitis group than the mild group and hence contributing to 
the increased NLR. 
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 This persistent lymphopenia has been attributed to 
progressive inflammation, bacteremia or sepsis in intensive care 
patients in other studies.24 Uncontrolled inflammation is thought to 
precipitate lymphopenia by redistribution of lymphocytes, 
accelerated apoptosis and hence lymphopenia responsible for 
higher mortality in patients with septic shock. 
 Similar to my study, Pezzilli et al who compared patients of 
acute pancreatitis with other acute abdominal conditions, reported 
a lymphopenia on day 1 in acute pancreatitis patients which 
persisted on days 3 and 5 following admission.24  
Similarly, Takeyama in his study noted that lymphocytes 
were significantly lower in severe pancreatitis patients who 
subsequently developed infective complications. Further, they 
noticed that it was the CD 8 positive lymphocytes which 
underwent apoptosis leading to impaired cellular immunity and in 
turn to infective complications. 
 It is this varying trend of neutrophils and lymphocytes that 
led to the proposal of assessing the neutrophilic lymphocytic ratio 
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as a predictive and a single factor than either of the component 
alone. 
 The Neutrophilic Lymphocytic Ratio has been evaluated in 
many benign and malignant conditions and a high NLR has been 
associated with poor outcome. A study was done which evaluated 
NLR in acute coronary syndrome and reported that an elevated 
NLR predicted in-hospital death and 6-month mortality. It was also 
associated with early hospital death and heart failure following 
myocardial infarction. 
 Similarly, NLR was evaluated in predicting cancer 
recurrence, disease free survival in patients with Hepatocellular 
cancer (HCC) and colorectal liver metastasis who underwent 
surgery and found that an elevated NLR was associated with a 
poor outcome. 
 NLR has been shown to reflect SOFA (Sequential Organ 
Failure Assessment) and APACHE II scores in patients in 
intensive care setting. It is these scores which are also used in 
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predicting severity in acute pancreatitis. So, NLR has been 
evaluated in predicting the severity in acute pancreatitis. 
 In my study, Neutrophilic Lymphocytic Ratio was assessed 
between mild and severe pancreatitis on day0, day1 and day 2 of 
admission. As per (chart 7), the NLR seems to represent a dynamic 
process where in it tends to return to normalcy in mild pancreatitis 
whereas it s persistently high in severe acute pancreatitis. 
 The difference in NLR pattern between the mild and severe 
acute pancreatitis was analyzed by independent sample t test and 
was found to be statistically significant (p < 0.05). 
 This variation in NLR was analyzed by Suppiah A et al and 
they reported that NLR was raised significantly in poor prognosis 
group than the favourable group. In their study the NLR was 
comparable at baseline that is at the time of admission. The NLR 
then gradually returned towards normal in favourable group while 
was persistently high in the poor prognosis group which is similar 
to my study.  
72 
 
 Similar study was conducted by Azab et al and they reported 
NLR to be superior to the total WBC count or individual 
neutrophil and lymphocyte counts in predicting ICU admission and 
death in acute pancreatitis patients. They further proceeded and 
recommended a cut-off value of ≥ 4.7 to identify poor outcome in 
acute pancreatitis.33 
 Another study conducted by Vedat goral et al in acute 
pancreatitis also reported that the leukocyte/ lymphocyte ratio is a 
simple test to indicate the severity of the disease.34 
 The benefit of my study is that NLR can be calculated by just 
doing a total WBC and a differential count. In comparison to other 
severity scoring systems, where there are multiple parameters 
required to  calculate the prognosis, NLR analysis just needs a 
single blood test needs to be done serially. 
 In some systems like the Ranson‟s and glascow scoring 
systems which can be calculated only after 48hrs of admission, the 
crucial period in management of acute pancreatitis is lost leading 
to a worse prognosis. In my study, NLR can be done at the time of 
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admission and can be serially monitored which can act as a guide 
to detect those patients progressing to severe pancreatitis. Those 
patients progressing to severe pancreatitis can be identified earlier 
and can be managed intensively and hence reduce the morbidity 
and mortality. 
 NLR is a cost effective, simple tool which can be calculated 
in any level care of hospital be it a secondary care or a tertiary care 
hospital. India being a developing country has a low Doctor: 
Patient ratio and limited facilities are available at the peripherally 
located hospitals. With alcohol induced pancreatitis being more 
common among the low socioeconomic status, multiple blood tests 
would be a burden for them. In that case, differential WBC count 
would be a cheaper and an easier blood test that can be performed 
and the NLR thus calculated can be used as a guide to refer poor 
prognosis patients to a higher center for intensive care and 
management. 
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CONCLUSION 
  
 In my study, Neutrophilic Lymphocytic Ratio has proved to be 
a single indicator in assessing the severity of acute pancreatitis.  
          NLR can be easily calculated and is a routine workup 
investigation that is done in all patients at the time of admission. Being a 
routine investigation, it bears no additional cost to the patient. 
 NLR seems to correlate well with the severity and outcome of 
acute pancreatitis. Continuous monitoring on each day will provide a 
dynamic reflection of the immunity and inflammatory response of the body 
to pancreatitis and hence predict the prognosis earlier. 
 NLR assessment trespasses the limitation of Ranson‟s scoring 
system that, it can be used at the time of admission itself and monitoring is 
possible in the first 48 hours. It covers the limitation of APACHE II scoring 
system in a way that it avoids multiple parameters needed for assessment. 
However, as of now APACHE II is considered the most useful the most 
useful test to predict severity. 
 Still further studies need to be performed to find out if we can 
predict an optimal Neutrophilic Lymphocytic Ratio which can delineate mild 
pancreatitis and those progressing to severe pancreatitis.  
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 As of now, only the study by Azab et al has proposed a 
neutrophil lymphocyte ratio value of ≥ 4.7 in predicting the severity in acute 
pancreatitis.33 However, as per Suppiah et al, this value has a high sensitivity 
(90.9 %) but a low specificity (22 %).24 
 So, Future studies are needed which can optimize the NLR and 
investigate if its incorporation would increase the accuracy of the current 
Acute pancreatitis prognostic scoring systems. 
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SUMMARY 
 
Acute pancreatitis is still one of the most common causes of 
emergency hospital admissions in India. The overall mortality due to acute 
pancreatitis has remained 10-15% in the past 20 years. Accurate predictors 
of the severity of acute pancreatitis are important because they influence 
clinical decision making. In this study, we evaluated 100 patients of acute 
pancreatitis and we found that pancreatitis is more common in males and 
alcohol being most common etiological factor.  
 Neutrophilic Lymphocytic Ratio (NLR) was calculated among these 
patients and was found to be increased in acute pancreatitis. It was 
significantly higher in severe pancreatitis patients than the mild pancreatitis 
patients. 
The NLR seems to persistently rise in poor prognostic patients when it 
was serially calculated. Hence, it is a dynamic indicator of the severity of the 
disease. 
NLR can be easily assessed. It can be calculated from a blood test 
which is routinely done for all patients at the time of admission. It is thus a 
cost effective tool.  
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NLR is a simple, single indicator of the prognosis of pancreatitis 
which would help in providing aggressive treatment to those patients 
progressing to severe pancreatitis. 
Future studies are needed which would incorporate this NLR into the 
current scoring systems and thus increase their accuracy. 
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ANNEXURES 
 
 
 
SL NAME AGE SEX IP NO. SR. AMYLASE USG/CT  FINDING ATLANTA
NO NLR NLR NLR CLASSIFICATION
1 SHANKAR 32 M 13103 2.03 2.39 2.46 224 ACUTE PANCREATITIS MILD
65 32 3 67 28 5 69 28 3 WITH ASCITES
2 MANOHARAN 48 M 7029 3.57 2.46 2.39 413 ACUTE PANCREATITIS MILD
75 21 4 69 28 3 67 28 5
3 ANBU 50 M 19199 3.33 2.18 2.42 568 ACUTE PANCREATITIS
70 21 9 61 28 2 63 26 2 WITH FLUID COLLECTION MILD
HEAD OF PANCREAS
4 ANBU 50 M 20836 2.59 2.59 2.39 339 ACUTE PANCREATITIS MILD
70 27 3 70 27 3 67 28 5 WITH ASCITES
5 SARAVANAN 36 M 5998 1.62 2.03 2.39 169 ACUTE PANCREATITIS MILD
60 37 3 65 32 3 67 28 5 WITH RETROPERITONEAL
FASCIAL INFLAMMATION
6 LEELAIHARAN 38 M 20835 2.77 5.00 9.56 461 DIFFUSELY ENLARGED SEVERE
72 26 2 80 16 4 86 9 5 HYPOECHOIC PANCREAS
ACUTE PANCREATITIS
7 ANAND 27 M 20373 5.13 3.33 1.62 339 ACUTE PANCREATITIS WITH MILD
82 16 2 70 21 21 60 37 3  LEFT PLEURAL EFFUSION
8 MURUGAN 38 M 18988 4.44 3.33 2.18
80 18 2 70 21 9 61 28 2 297 ACUTE PANCREATITIS MILD
9 RAJA 40 M 17948 3.57 3.33 2.39 447 ACUTE PANCREATITIS MILD
75 21 4 70 21 9 67 28 5
10800 8800 8600
10300 8500 8500
580065007100
14000 11800 10600
760068006800
6300
DAY 0 DAY 1 DAY 2
6200
TC/DCTC/DC
10800 8600
TC/DC
7000 7200
9900 8600 8000
10800 8600 6700
SL NAME AGE SEX IP NO. SR. AMYLASE USG/CT  FINDING ATLANTA
NO NLR NLR NLR CLASSIFICATION
10 BASKAR 31 M 9316 1.45 2.00 2.52 365 ACUTE PANCREATITIS WITH SEVERE
58 40 2 66 33 4 68 27 5 PSEUDOCYST PANCREAS
11 KRISHNA 52 M 9391 1.57 5.13 9.56 206 ACUTE FLUID COLLECTION SEVERE
MOORTHY 58 37 3 82 16 2 86 9 5 WITH ASCITES
12 SAKTHIVEL 35 M 10373 1.88 4.44 5.13 155 ACUTE PANCREATITIS SEVERE
64 34 2 80 18 2 82 16 2 WITH PSEUDOCYST
13 ANNADURAI 38 M 10311 1.35 3.33 2.39 365 ACUTE PANCREATITIS MILD
54 40 6 70 21 9 67 28 5
14 SATYA 52 M 5158 1.77 3.33 2.39 218 ACUTE PANCREATITIS MILD
62 35 3 70 21 9 67 28 5 PERIPANCREATIC
INFLAMMATION
15 THAMEEM 30 M 7093 2.46 2.92 3.33 292 ACUTE PANCREATITIS MILD
ANSARI 69 28 3 76 26 8 70 21 9
16 SELVAM 38 M 2948 9.56 10.0 11.0 317 ACUTE NECROTISING SEVERE
86 9 5 90 9 1 88 8 4 PANCREATITIS WITH ABSCESS
17 RAJI 25 M 19158 3.33 3.57 2.46 486 ACUTE PANCREATITIS MILD
70 21 9 75 21 4 69 28 3
18 ANTHONY 38 M 17278 3.57 3.89 3.33 380 ACUTE PANCREATITIS MILD
75 21 4 74 19 7 70 21 9
19 MUNUSAMY 40 M 6652 6.46 11.00 13.8 570 ACUTE PANCREATITIS SEVERE
84 13 3 88 8 4 83 6 11 WITH NECROSIS
5800 6300 6300
6800
12600 12000 11600
8400 7800
9900 8600
6600 8600 6700
DAY 0 DAY 1
7900 7800 7700
DAY 2
TC/DC TC/DC TC/DC
6500
7400 8100 8000
9200 8500 5600
7800 7500 6800
8600 10600 11400
SL NAME AGE SEX IP NO. SR. AMYLASE USG/CT  FINDING ATLANTA
NO NLR NLR NLR CLASSIFICATION
20 POIYAMANI 34 M 21150 4.44 3.57 3.41 361 ACUTE PANCREATITIS MILD
80 18 2 75 21 4 75 22 3
21 RAVI 30 M 19280 3.90 4.21 3.62 421 ACUTE PANCREATITIS WITH MILD
78 20 2 80 19 1 76 21 3 ASCITES
22 BABU 41 M 19217 3.62 3.57 3.57 510 ACUTE PANCREATITIS MILD
76 21 3 75 21 4 75 21 4
23 NAGARAJ 35 M 18081 4.21 5.00 3.90 551 ACUTE PANCREATITIS MILD
80 19 1 80 16 4 78 20 2
24 JOSEPH 25 M 15756 3.90 4.21 3.57 487 ACUTE PANCREATITIS MILD
78 20 2 80 19 1 75 21 4
25 MUTHU 30 M 9918 7.00 8.20 7.50 361 ACUTE PANCREATITIS MILD
MANICKAM 84 12 4 82 10 8 75 10 15 WITH FLUID COLLECTION
26 AYYANAR 26 M 9375 5.13 4.44 3.57 468 ACUTE PANCREATITIS MILD
82 16 2 80 18 2 75 21 4
27 VENKATESH 37 M 9264 6.46 5.86 5.13 471 ACUTE PANCREATITIS WITH MILD
84 13 5 82 14 4 82 16 2 ASCITES
28 MANOHARAN 48 M 7029 3.57 3.62 3.90 268 ACUTE PANCREATITIS MILD
75 21 4 76 21 3 78 20 2
29 DILLIBABU 38 M 10696 4.82 13.8 22.0 615 ACUTE NECROTISING SEVERE
82 17 11 83 6 11 88 4 5 PANCREATITIS
30 MARY 34 F 17656 3.33 2.39 2.77 357 ACUTE PANCREATITIS MILD
70 21 9 67 28 5 72 26 2
TC/DC TC/DC TC/DC
10200
8900 8600 7800
9200 9400 8200
7400
9200 8200 7400
10800 11000 10200
11600
10800 8600
8400 6800
8200 8600 7800
7800 8400 7800
DAY 0 DAY 1 DAY 2
11800 10600
6800 7200 8200
5800 9600 9800
SL NAME AGE SEX IP NO. SR. AMYLASE USG/CT  FINDING ATLANTA
NO NLR NLR NLR CLASSIFICATION
31 THARANIVELU 60 m 95413 4.21 6.33 3.90 457 ACUTE PANCREATITIS MILD
80 19 1 76 12 3 78 20 2
32 OMPRAKASH 40 M 91129 3.57 4.21 3.62 513 ACUTE PANCREATITIS MILD
75 21 4 80 19 1 76 21 3 WITH ASCITES
33 BABU 28 M 8284 11.0 12.6 11.7 719 ACUTE NECROTISING SEVERE
88 8 4 88 7 5 82 7 11 PANCREATITIS
34 NELSON 40 M 3422 6.46 5.13 3.90 415 ACUTE PANCREATITIS MILD
84 13 3 82 16 2 78 20 2
35 SATYA 50 M 5159 4.44 3.62 3.33 371 ACUTE PANCREATITIS MILD
80 18 2 76 21 3 70 21 4
36 KALAIARASAN 35 M 650 2.77 2.39 2.03 365 ACUTE PANCREATITIS MILD
72 26 2 67 28 3 65 32 3 WITH ASCITES
37 SELVAM 38 M 2843 7.50 5.86 6.46 513 ACUTE PANCREATITIS MILD
75 10 15 82 14 4 84 13 3 WITH FLUID COLLECTION
38 SUDHAKAR 26 M 3025 10.0 10.3 9.56 625 ACUTE PANCREATITIS SEVERE
90 9 1 82 8 10 86 9 5 WITH PSEUDOCYST
39 VENKAT 41 M 519 2.63 3.62 3.33 484 RESOLVING PANCREATITIS MILD
71 27 2 76 21 3 70 21 9
40 DOWLAY 43 M 10814 5.00 3.57 2.46 371 ACUTE PANCREATITIS MILD
80 16 4 75 21 4 69 28 3
41 MURUGESAN 40 M 10993 3.90 3.89 2.77 461 ACUTE PANCREATITIS MILD
78 20 2 74 19 7 72 26 2
DAY 0 DAY 1 DAY 2
TC/DC TC/DC TC/DC
7600 6700 9400
6800 12300 11800
8200 9500 4700
4300 5400 5100
12700 13500 7500
7700 4100
8700 7800 9000
7800 6100 6200
5600
7800 10600 9700
9600 7400 7900
7600 6800 9600
SL NAME AGE SEX IP NO. SR. AMYLASE USG/CT  FINDING ATLANTA
NO NLR NLR NLR CLASSIFICATION
42 RAGAVAN 44 M 10797 4.56 4.21 4.44 375 ACUTE PANCREATITIS MILD
82 18 0 80 19 1 80 18 2
43 SELVAKUMAR 37 M 10731 5.93 6.23 6.31 380 ACUTE PANCREATITIS WITH SEVERE
83 14 3 81 13 6 82 13 5 ASCITES
44 DILLIBABU 38 M 10696 11.71 12.6 13.8 514 ACUTE NECROTISING SEVERE
82 7 11 88 7 5 83 6 11 PANCREATITIS
45 ANAND 37 M 10483 7.50 5.13 4.44 475 ACUTE PANCREATITIS MILD
75 10 15 82 16 2 80 18 2
46 KANNAN 39 M 5955 5.93 4.75 4.56 416 ACUTE PANCREATITIS MILD
83 14 3 76 16 6 82 18 0
47 UDHAYA KUMAR27 M 5192 6.31 5.60 5.13 518 ACUTE PANCREATITIS MILD
82 13 5 84 15 1 82 16 2
48 ROSE 50 M 4215 5.13 5.00 5.47 564 ACUTE PANCREATITIS MILD
82 16 2 80 16 4 82 15 3
49 ANBARASAN 40 M 996 6.62 6.83 5.3 487 ACUTE PANCREATITIS MILD
86 13 1 82 12 6 80 15 5
50 ANAND 26 M 20373 4.44 3.57 4.21 587 ACUTE PANCREATITIS MILD
80 18 2 75 21 4 80 19 1
51 SHANKAR 29 M 20791 6.23 3.90 4.44 483 ACUTE PANCREATITIS MILD
81 13 6 78 20 2 80 18 2
52 SEAGU 32 M 19600 3.57 2.46 3.24 247 ACUTE PANCREATITIS MILD
75 21 4 69 28 3 68 21 1
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NO NLR NLR NLR CLASSIFICATION
53 NATRAJ 52 M 19551 9.56 11.0 12.6 630 ACUTE PANCREATITIS WITH SEVERE
86 9 5 88 8 4 88 7 5 PANCREATIC ABSCESS
54 RAGHU 37 M 19508 7.50 5.13 3.89 213 ACUTE PANCREATITIS MILD
75 10 15 82 16 2 74 19 7
55 PONNUSAMY 40 M 17965 6.31 5.86 4.21 245 ACUTE PANCREATITIS MILD
82 13 5 82 14 4 80 19 1
56 SHEEK 37 F 16898 6.23 5.19 4.71 315 ACUTE PANCREATITIS MILD
81 13 6 83 16 1 80 17 3
57 SUGUMAR 33 M 15399 10.0 9.56 8.20 245 ACUTE PANCREATITIS WITH MILD
90 9 1 86 9 5 82 10 8 FLUID COLLECTION
58 ROSEMARY 40 F 15912 5.86 4.44 3.33 413 ACUTE PANCREATITIS MILD
82 14 4 80 18 2 70 21 9
59 RAMSINGH 56 M 14402 3.57 2.46 2.03 467 ACUTE PANCREATITIS MILD
75 21 4 69 28 3 65 32 3
60 RAJA 22 M 14251 6.46 5.13 4.21 415 ACUTE PANCREATITIS MILD
84 13 3 82 16 2 80 19 1
61 SUNDARAPANDIAN24 M 13881 9.56 10.0 11.0 679 ACUTE PANCREATITIS WITH SEVERE
86 9 5 90 9 1 88 8 4 RENAL FAILURE
62 HUSSAIN 40 M 13887 6.83 5.53 4.21 345 ACUTE PANCREATITIS MILD
82 12 6 83 15 2 80 19 1
63 SIVAKUMAR 43 M 13685 7.00 6.46 6.23 274 ACUTE PANCREATITIS MILD
84 12 4 84 13 3 81 13 6
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7800 8200 9600
9800 10200 11100
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64 JAYAPAL 27 M 12368 4.56 4.75 4.44 276 ACUTE PANCREATITIS MILD
82 18 0 76 16 6 80 18 2
65 DURAI 56 M 13171 6.46 6.31 6.23 213 ACUTE PANCREATITIS MILD
84 13 3 82 13 5 81 13 6
66 SEBASTIAN RAJ 26 M 12668 7.50 6.83 3.24 317 ACUTE PANCREATITIS MILD
75 10 15 82 12 6 68 21 1
67 RAMDAS 36 M 12223 4.21 3.90 3.60 148 ACUTE PANCREATITIS MILD
80 19 1 78 20 2 72 20 8
68 RAJENDRAN 57 M 11705 4.82 12.6 11.0 468 ACUTE PANCREATITIS WITH SEVERE
82 17 11 88 7 5 88 8 4 ARDS
69 VEERAMANI 34 M 10880 8.70 9.78 10.0 461 ACUTE NECROTISING SEVERE
87 10 3 88 9 3 90 9 1 PANCREATITIS WITH GB SLUDGE
70 SHANTHAKUMAR30 M 11664 6.83 6.31 5.9 315 ACUTE PANCREATITIS MILD
82 12 6 82 13 5 83 14 3
71 DURAI 47 M 11407 5.13 3.62 3.6 461 ACUTE PANCREATITIS MILD
82 16 2 76 21 3 75 21 4
72 RAMESH 31 M 11381 8.20 7.00 4.2 264 ACUTE PANCREATITIS MILD
82 10 8 84 12 4 80 19 1
73 AYATH BASHA 52 M 10953 6.46 5.13 4.4 313 ACUTE PANCREATITIS MILD
84 13 3 82 16 2 80 18 2
74 AUGUSTIN 48 M 10920 9.56 8.20 7.5 415 ACUTE PANCREATITIS MILD
86 9 5 82 10 8 75 10 15
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75 THANGARAJ 38 M 10450 11.7 12.57 10.0 597 ACUTE NECROTISING SEVERE
82 7 11 88 7 5 90 9 1 PANCREATITIS
76 POONGAVANAM46 M 10065 4.56 5.19 5.1 275 ACUTE PANCREATITIS MILD
82 18 0 83 16 1 82 16 2
77 ALIM 40 M 10482 7.33 6.23 2.8 148 ACUTE PANCREATITIS MILD
88 12 0 81 13 6 72 26 2
78 THANGAVEL 40 M 10421 13.8 14.83 12.6 754 ACUTE HEMORRHAGIC SEVERE
83 6 11 89 6 5 88 7 5 PANCREATITIS
79 KALAISELVAN 30 M 10299 7.08 6.23 5.9 245 ACUTE PANCREATITIS MILD
85 12 3 81 13 6 83 14 3
80 RAJESH 37 M 10521 8.20 6.54 5.5 218 ACUTE PANCREATITIS MILD
82 10 8 85 13 2 83 15 2
81 SUNDAR 35 M 10279 6.54 5.60 6.1 283 ACUTE PANCREATITIS MILD
85 13 2 84 15 1 86 14 0
82 JAGAN 40 M 10270 8.00 4.69 3.3 473 ACUTE PANCREATITIS MILD
88 11 1 75 16 9 76 23 1
83 JAIGANESH 42 M 10014 3.95 5.06 4.8 297 ACUTE PANCREATITITS MILD
79 20 1 81 16 3 76 16 6
84 CHANDRAN 40 M 9980 7.27 5.47 5.1 260 ACUTE PANCREATITIS MILD
80 11 9 82 15 3 82 16 2
85 RAMADOSS 46 M 9723 5.47 3.33 3.7 350 ACUTE PANCREATITIS MILD
82 15 3 70 21 9 77 21 2
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86 RAJA 21 M 9769 4.59 5.13 4.9 394 ACUTE PANCREATITIS WITH MILD
78 17 5 82 16 2 79 16 5 ASCITES
87 KRISHNAN 54 M 9513 9.11 6.67 0.2 439 ACUTE PANCREATITIS MILD
82 9 9 80 12 8 4 18 2
88 MUTHUKUMAR21 M 9040 7.08 6.58 5.1 393 ACUTE PANCREATITIS MILD
85 12 3 79 12 1 82 16 2
89 SYED BUHARI 45 M 9012 9.00 9.56 8.5 785 ACUTE NECROTISING SEVERE
90 10 0 86 9 5 85 10 5 PANCREATITIS
90 RAVI 48 M 8584 5.60 5.53 4.7 245 ACUTE PANCREATITIS MILD
84 15 1 83 15 2 80 17 3
91 NARAYANAN 50 M 8801 9.67 10.00 11.0 746 ACUTE PANCREATITIS WITH SEVERE
87 9 4 90 9 1 88 8 4 PSEUDOCYST
92 KUMAR 32 M 8361 2.71 3.04 3.0 245 ACUTE PANCREATITIS MILD
76 28 6 79 26 5 72 24 4
93 KUPPAN 45 M 7069 5.60 5.93 4.4 243 ACUTE PANCREATITIS MILD
84 15 1 83 14 3 80 18 2
94 PALANI 40 M 7066 6.08 5.60 5.2 336 ACUTE PANCREATITIS MILD
79 13 8 84 15 1 83 16 1
95 SIVASHANKAR 27 M 7047 2.39 3.84 3.6 426 ACUTE PANCREATITIS MILD
67 28 5 73 19 8 76 21 3
96 SENTHIL 48 M 6870 2.88 3.57 3.3 532 ACUTE PANCREATITIS MILD
69 24 7 75 21 4 70 21 9
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97 PRASAD 22 M 6618 11.4 12.57 10.3 765 ACUTE PANCREATITIS WITH SEVERE
91 8 1 88 7 5 82 8 10 ARDS
98 SELVI 35 F 5682 7.25 7.00 5.5 432 ACUTE PANCREATITIS MILD
87 12 1 84 12 4 83 15 2
99 RAJENDRAN 43 M 4933 3.30 3.57 2.9 254 ACUTE PANCREATITIS MILD
76 23 1 75 21 4 72 25 3
100 RAJKUMAR 40 M 2693 5.60 5.93 3.6 345 ACUTE PANCREATITIS MILD
84 15 1 83 14 3 76 21 3
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